Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Lesional-targeting of neuroprotection to the inflammatory penumbra in experimental multiple sclerosis.

Al-Izki S, Pryce G, Hankey DJ, Lidster K, von Kutzleben SM, Browne L, Clutterbuck L, Posada C, Edith Chan AW, Amor S, Perkins V, Gerritsen WH, Ummenthum K, Peferoen-Baert R, van der Valk P, Montoya A, Joel SP, Garthwaite J, Giovannoni G, Selwood DL, Baker D.

Brain. 2014 Jan;137(Pt 1):92-108. doi: 10.1093/brain/awt324. Epub 2013 Nov 27.

PMID:
24287115
2.

The histone deacetylase inhibitor UCL67022 has potent activity in multiple myeloma and non-Hodgkin lymphoma pre-clinical models.

Maharaj L, Marson CM, Middleton BJ, Rioja AS, Perry J, Oakervee H, Cavenagh J, Joel SP, Popat R.

Br J Haematol. 2013 Oct;163(1):135-9. doi: 10.1111/bjh.12456. Epub 2013 Jul 9. No abstract available.

PMID:
23834265
3.

Methylseleninic acid antagonizes the cytotoxic effect of bortezomib in mantle cell lymphoma cell lines through modulation of Bcl-2 family proteins.

Kassam S, Juliger S, Jia L, Joel SP.

Br J Haematol. 2012 Jan;156(2):286-9. doi: 10.1111/j.1365-2141.2011.08861.x. Epub 2011 Sep 13. No abstract available.

PMID:
21910718
4.

Methylseleninic acid inhibits HDAC activity in diffuse large B-cell lymphoma cell lines.

Kassam S, Goenaga-Infante H, Maharaj L, Hiley CT, Juliger S, Joel SP.

Cancer Chemother Pharmacol. 2011 Sep;68(3):815-21. doi: 10.1007/s00280-011-1649-1. Epub 2011 Apr 26.

PMID:
21519842
5.

Capabilities of HPLC with APEX-Q nebulisation ICP-MS and ESI MS/MS to compare selenium uptake and speciation of non-malignant with different B cell lymphoma lines.

Goenaga-Infante H, Kassam S, Stokes E, Hopley C, Joel SP.

Anal Bioanal Chem. 2011 Feb;399(5):1789-97. doi: 10.1007/s00216-010-4474-1. Epub 2010 Dec 8.

PMID:
21140135
6.

The association of CCND1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers.

Noel EE, Yeste-Velasco M, Mao X, Perry J, Kudahetti SC, Li NF, Sharp S, Chaplin T, Xue L, McIntyre A, Shan L, Powles T, Oliver RT, Young BD, Shipley J, Berney DM, Joel SP, Lu YJ.

Am J Pathol. 2010 Jun;176(6):2607-15. doi: 10.2353/ajpath.2010.090780. Epub 2010 Apr 15.

7.

Identification of genomic changes associated with cisplatin resistance in testicular germ cell tumor cell lines.

Noel EE, Perry J, Chaplin T, Mao X, Cazier JB, Joel SP, Oliver RT, Young BD, Lu YJ.

Genes Chromosomes Cancer. 2008 Jul;47(7):604-13. doi: 10.1002/gcc.20564.

PMID:
18384131
8.
9.

GAMEC--a new intensive protocol for untreated poor prognosis and relapsed or refractory germ cell tumours.

Shamash J, Powles T, Ansell W, Berney D, Stebbing J, Mutsvangwa K, Wilson P, Asterling S, Liu S, Wyatt P, Joel SP, Oliver RT.

Br J Cancer. 2007 Aug 6;97(3):308-14. Epub 2007 Jul 3. Erratum in: Br J Cancer. 2007 Oct 22;97(8):1188. Berney, Dan [added].

10.

A feasibility, pharmacokinetic and frequency-escalation trial of intraperitoneal chemotherapy in high risk gastrointestinal tract cancer.

Seymour MT, Trigonis I, Finan PJ, Halstead F, Dunham R, Wilson G, Farrugia D, Chester JD, King J, Brown CB, Slevin ML, Joel SP.

Eur J Surg Oncol. 2008 Apr;34(4):403-9. Epub 2007 Jul 2.

PMID:
17604939
11.

The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.

Strauss SJ, Higginbottom K, Jüliger S, Maharaj L, Allen P, Schenkein D, Lister TA, Joel SP.

Cancer Res. 2007 Mar 15;67(6):2783-90.

12.

Morphine analgesia in cancer pain: role of the glucuronides.

Penson RT, Joel SP, Gloyne A, Clark S, Slevin ML.

J Opioid Manag. 2005 May-Jun;1(2):83-90.

PMID:
17319252
13.

Structure-activity relationships of aryloxyalkanoic acid hydroxyamides as potent inhibitors of histone deacetylase.

Marson CM, Mahadevan T, Dines J, Sengmany S, Morrell JM, Alao JP, Joel SP, Vigushin DM, Charles Coombes R.

Bioorg Med Chem Lett. 2007 Jan 1;17(1):136-41. Epub 2006 Sep 30.

PMID:
17046252
14.

Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity.

Strauss SJ, Maharaj L, Hoare S, Johnson PW, Radford JA, Vinnecombe S, Millard L, Rohatiner A, Boral A, Trehu E, Schenkein D, Balkwill F, Joel SP, Lister TA.

J Clin Oncol. 2006 May 1;24(13):2105-12. Epub 2006 Apr 10.

PMID:
16606971
15.

Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides.

Marson CM, Savy P, Rioja AS, Mahadevan T, Mikol C, Veerupillai A, Nsubuga E, Chahwan A, Joel SP.

J Med Chem. 2006 Jan 26;49(2):800-5.

PMID:
16420064
16.

Clinical response to morphine in cancer patients and genetic variation in candidate genes.

Ross JR, Rutter D, Welsh K, Joel SP, Goller K, Wells AU, Du Bois R, Riley J.

Pharmacogenomics J. 2005;5(5):324-36.

PMID:
16103897
17.

Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma.

Ord JJ, Streeter E, Jones A, Le Monnier K, Cranston D, Crew J, Joel SP, Rogers MA, Banks RE, Roberts IS, Harris AL.

Br J Cancer. 2005 Jun 20;92(12):2140-7.

18.

Stability of morphine sulphate and diamorphine hydrochloride in intrasite gel.

Zeppetella G, Joel SP, Ribeiro MD.

Palliat Med. 2005 Mar;19(2):131-6.

PMID:
15810752
19.

Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin.

Joel SP, Papamichael D, Richards F, Davis T, Aslanis V, Chatelut E, Locke K, Slevin ML, Seymour MT.

Clin Pharmacol Ther. 2004 Jul;76(1):45-54.

PMID:
15229463
20.

s-thalidomide has a greater effect on apoptosis than angiogenesis in a multiple myeloma cell line.

Liu WM, Strauss SJ, Chaplin T, Shahin S, Propper DJ, Young BD, Joel SP, Malpas JS.

Hematol J. 2004;5(3):247-54.

PMID:
15167912
21.

The bioavailability of morphine applied topically to cutaneous ulcers.

Ribeiro MD, Joel SP, Zeppetella G.

J Pain Symptom Manage. 2004 May;27(5):434-9.

22.

Histone acetylation-mediated regulation of genes in leukaemic cells.

Chambers AE, Banerjee S, Chaplin T, Dunne J, Debernardi S, Joel SP, Young BD.

Eur J Cancer. 2003 May;39(8):1165-75.

PMID:
12736119
23.

The schedule-dependent effects of etoposide in leukaemic cell lines: a function of concentration and duration.

Liu WM, Joel SP.

Cancer Chemother Pharmacol. 2003 Apr;51(4):291-6. Epub 2003 Mar 5.

PMID:
12721756
24.

Structure-activity relationships of some opiate glycosides.

Stachulski AV, Scheinmann F, Ferguson JR, Law JL, Lumbard KW, Hopkins P, Patel N, Clarke S, Gloyne A, Joel SP.

Bioorg Med Chem Lett. 2003 Mar 24;13(6):1207-14.

PMID:
12643945
25.

Phase I and pharmacokinetic study of intravenous irinotecan plus oral ciclosporin in patients with fuorouracil-refractory metastatic colon cancer.

Chester JD, Joel SP, Cheeseman SL, Hall GD, Braun MS, Perry J, Davis T, Button CJ, Seymour MT.

J Clin Oncol. 2003 Mar 15;21(6):1125-32.

PMID:
12637480
26.
27.

A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer.

Cheeseman SL, Joel SP, Chester JD, Wilson G, Dent JT, Richards FJ, Seymour MT.

Br J Cancer. 2002 Aug 12;87(4):393-9.

29.

The bioavailability and pharmacokinetics of subcutaneous, nebulized and oral morphine-6-glucuronide.

Penson RT, Joel SP, Roberts M, Gloyne A, Beckwith S, Slevin ML.

Br J Clin Pharmacol. 2002 Apr;53(4):347-54.

31.

DNA damage is able to induce senescence in tumor cells in vitro and in vivo.

te Poele RH, Okorokov AL, Jardine L, Cummings J, Joel SP.

Cancer Res. 2002 Mar 15;62(6):1876-83.

32.

Limited phase I study of morphine-3-glucuronide.

Penson RT, Joel SP, Clark S, Gloyne A, Slevin ML.

J Pharm Sci. 2001 Nov;90(11):1810-6.

PMID:
11745739
33.

Randomized placebo-controlled trial of the activity of the morphine glucuronides.

Penson RT, Joel SP, Bakhshi K, Clark SJ, Langford RM, Slevin ML.

Clin Pharmacol Ther. 2000 Dec;68(6):667-76.

PMID:
11180027
34.

The pharmacokinetics of morphine and morphine glucuronide metabolites after subcutaneous bolus injection and subcutaneous infusion of morphine.

Stuart-Harris R, Joel SP, McDonald P, Currow D, Slevin ML.

Br J Clin Pharmacol. 2000 Mar;49(3):207-14.

35.
37.
38.

Re: Loss of DNA mismatch repair: effects on the rate of mutation to drug resistance.

Liu WM, te Poele RH, Joel SP.

J Natl Cancer Inst. 1998 Feb 4;90(3):246-7. No abstract available.

PMID:
9462684
39.

A pharmacokinetic study of sublingual aerosolized morphine in healthy volunteers.

Watson NW, Taylor KM, Joel SP, Slevin ML, Eden OB.

J Pharm Pharmacol. 1996 Dec;48(12):1256-9.

PMID:
9004187
40.

Therapeutic monitoring of continuous infusion etoposide in small-cell lung cancer.

Joel SP, Ellis P, O'Byrne K, Papamichael D, Hall M, Penson R, Nicholls S, O'Donnell C, Constantinou A, Woodhull J, Nicholson M, Smith I, Talbot D, Slevin M.

J Clin Oncol. 1996 Jun;14(6):1903-12.

PMID:
8656259
41.

Predicting etoposide toxicity: relationship to organ function and protein binding.

Joel SP, Shah R, Clark PI, Slevin ML.

J Clin Oncol. 1996 Jan;14(1):257-67.

PMID:
8558207
42.

Respiratory depression following morphine and morphine-6-glucuronide in normal subjects.

Thompson PI, Joel SP, John L, Wedzicha JA, Maclean M, Slevin ML.

Br J Clin Pharmacol. 1995 Aug;40(2):145-52.

43.

A specific radioimmunoassay for the determination of morphine-6-glucuronide in human plasma.

Chapman DJ, Cross MJ, Joel SP, Aherne GW.

Ann Clin Biochem. 1995 May;32 ( Pt 3):297-302.

PMID:
7632034
44.

Pharmacological attempts to improve the bioavailability of oral etoposide.

Joel SP, Clark PI, Heap L, Webster L, Robbins S, Craft H, Slevin ML.

Cancer Chemother Pharmacol. 1995;37(1-2):125-33.

PMID:
7497581
45.

Stability of the i.v. and oral formulations of etoposide in solution.

Joel SP, Clark PI, Slevin ML.

Cancer Chemother Pharmacol. 1995;37(1-2):117-24.

PMID:
7497580
46.

Lack of effect of interferon alpha 2a upon fluorouracil pharmacokinetics.

Seymour MT, Patel N, Johnston A, Joel SP, Slevin ML.

Br J Cancer. 1994 Oct;70(4):724-8.

47.

A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity.

Clark PI, Slevin ML, Joel SP, Osborne RJ, Talbot DI, Johnson PW, Reznek R, Masud T, Gregory W, Wrigley PF.

J Clin Oncol. 1994 Jul;12(7):1427-35.

PMID:
8021734
48.
49.

Schedule-dependent topoisomerase II-inhibiting drugs.

Joel SP, Slevin ML.

Cancer Chemother Pharmacol. 1994;34 Suppl:S84-8. Review.

PMID:
8070033
50.

Etoposide dosage and pharmacodynamics.

Joel SP, Shah R, Slevin ML.

Cancer Chemother Pharmacol. 1994;34 Suppl:S69-75. Review.

PMID:
8070031

Supplemental Content

Support Center